Stretched services leaving psychiatrists ‘in emotional and ethical distress'
It comes as a survey of RCPsych members found almost three-quarters felt they had made decisions to admit or discharge people based on factors other than what is in the patient's best interests.
According to Dr Smith, 'long-term underinvestment and a failure to follow an evidence-based approach has led to an erosion of standards in the mental health system'.
She will add: 'Despite this, mental health staff across the NHS continue to provide outstanding care in the face of unprecedented demand and workforce pressures.
'Psychiatrists are committed to providing expert and timely treatment that prevents people entering mental health crisis.
'But the reality is that current targets are not based on patient outcomes. Pressures that override clinical judgment, combined with inadequate inpatient and community provision, are damaging the very foundations of compassionate, therapeutic and holistic care.
'Repeated failure to attend to the pressures facing mental health services mean that provisions are now so threadbare that psychiatrists are having to make life and death decisions based on financial rather than clinical concerns.
'At worst, these systemic pressures prevent clinicians from delivering the care they know is needed, risking people becoming more unwell, resulting in greater risk of mental health crisis and increased risk of suicide. This is causing deep distress and moral injury among psychiatrists.'
Of the 860 RCPsych members who completed the survey in England, 73% felt they had made decisions to admit or discharge patients based on factors outside clinical need.
Meanwhile, more than eight in 10 (81%) said they had experienced feelings of guilt, shame, burnout and frustration over these decisions.
Members said a lack of investment in community mental health services lead to more patients going into crisis, while a lack of affordable housing is causing delayed discharges.
Almost half (47%) of those who responded to the survey said they are facing delays in admitting or treating people because of a lack of local capacity.
Dr Smith will add: 'These findings paint a stark picture of longstanding systemic issues in the way mental health services are currently commissioned and delivered.'
She said the upcoming 10 Year Health Plan 'presents the perfect opportunity' for the Government to outline a 'clear ambition for the prevention and treatment of serious mental illness'.
'Alongside this, we need to see an updated long-term workforce plan with a recommitment to double medical school places as well as bolder promises to retain the workforce and increase specialty training places,' Dr Smith will tell delegates.
An NHS spokesperson, said: 'The pandemic has had a huge impact on the nation's mental health with NHS staff treating a million more people now than we did in 2019, which is why we've drastically expanded access and boosted our mental health workforce by over 40,000 staff.
'We know more needs to be done to increase access to inpatient services, which is why we are working with the Government on the upcoming NHS 10 year-plan to create a service that is better for patients and is fit for the future.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
16 minutes ago
- Daily Mail
Food for thought... how we comfort eat our way to 344,064 calories a year
We have all reached for a bar of chocolate or packet of crisps after a trying day. But our fondness for a snack when feeling down is adding many thousands of extra calories to our diets, a poll has revealed. A quarter of Britons questioned in the survey said they would describe themselves as an emotional eater – admitting to eating 28,672 'comfort calories' a month, or 344,064 a year. Almost nine in ten of those surveyed said they had eaten food out of boredom or sadness, despite not being hungry. Many said they felt guilty as a result. However, 78 per cent said they wanted to reduce the amount they eat because of feeling sensitive to weight gain. The most popular emotional nibbles were bags of crisps, chocolate bars, biscuits, bananas, buttered toast and instant noodles. Nuts, cheese, sausage rolls, and crumpets were also common snacks chosen to give us an emotional boost. Somewhat depressingly, four in ten of the 20,000 participants surveyed described food as their only real enjoyment in life. Psychologist Dr Becky Spelman said: 'Emotional eating is deeply rooted in how we were raised. 'Many of us were given treats as a reward for being good or to soothe us when we were upset, so food becomes more than just fuel; it's a source of emotional comfort.' She said recognising the pattern was the first step towards replacing habits with something that 'genuinely nurtures us emotionally'. 'Real change begins with kindness, with treating yourself like someone you care about, even when you're struggling,' Dr Spelman added. 'That shift in perspective is what helps break the cycle.' Dr Babak Ashrafi from Superdrug Online Doctor, which commissioned the survey, said: 'With the latest Government stats showing six in ten of us are obese or overweight, it seems many Brits need to break the cycle of emotional eating.'
The Sun
16 minutes ago
- The Sun
Weight loss jabs could be key to controlling asthma in thousands of Brits, say scientists
WEIGHT loss jabs could help control asthma symptoms in obese people, a study suggests - and it's not just about losing weight. The drugs should be explored as a potential treatment for obese people with asthma, who are "often resistant" to steroids, researchers said. 1 Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicking the hormone GLP-1 to regulate blood sugar and insulin levels and dull hunger pangs. They were initially developed as a treatment for people with type 2 diabetes - Ozempic is a key example. Several types of the drug are recommended to help tackle obesity on the NHS, including Wegovy or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like sleep apnoea, dementia and stroke. Now, an international team of experts are exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: "People with obesity and asthma are unique in that they are often resistant to steroid treatments. "We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids." People with a BMI of 30 or more have a much higher risk of having asthma than those with a lower BMI, according to the American Lung Association. It said extra weight around the chest and abdomen can constrict the lungs and make it more difficult to breathe. But research also suggests that fat tissue produces inflammatory substances that might affect the lungs and up the risk of asthma. Having asthma can also increase the risk of obesity, as symptoms can make it harder to be physically active and long-term steroid use can increase hunger, NHS Cambridge University Hospitals Trust suggests. For the new study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics "should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases". Prof Price added: "We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. "In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. WHO IS ELIGIBLE FOR WEIGHT LOSS JABS ON THE NHS? NHS eligibility for weight loss injections has expanded but still lags behind the number who could potentially benefit from taking them. Wegovy, medical name semaglutide, is only available for weight loss through specialist weight management clinics. Patients are typically expected to have tried other weight loss methods before getting a prescription. They may be eligible if their body mass index (BMI) is higher than 30, or higher than 27 if they have a weight-related health condition such as high blood pressure. Mounjaro, known as tirzepatide, is also available from GP practices but currently only to patients with a BMI of 40 or higher (or 37.5 if from a minority ethnic background) plus four weight-related health conditions. The medicines are currently being rationed to the patients most in need. NHS watchdog NICE estimates that more than three million Brits will ultimately be eligible. The GLP-1 injections are prescribed separately by GPs for people with type 2 diabetes, and patients should discuss this with their doctor. "Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further." Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: "Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs." Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: "Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. "Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. "Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. "It's too early to say whether these drugs would be effective for people with asthma more widely. "More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment." It's though that 7.2 million people in the UK have asthma, according to Asthma + Lung UK. Meanwhile, 64 per cent of adults aged 18 and above in England were estimated to be overweight or living with obesity between 2023 and 2024.
Western Telegraph
20 minutes ago
- Western Telegraph
Weight-loss jabs could help obese people control asthma, study suggests
The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'
